Loading...
Loading...
In a report published Monday, Piper Jaffray & Co. reiterated its Overweight rating on Supernus Pharmaceuticals
SUPN, and raised its price target from $12.00 to $15.00.
Piper Jaffray noted, “Supernus reported a 2Q12 net loss per share of ($0.61). With a tentative approval and clearer launch timeline for SUPN's extended-release (ER) formulation of topiramate (SPN-538; trade name is Trokendi XR) now in place (the launch is expected in 3Q13), there is now clear visibility on a transition to a commercial-stage company. The next potential milestone is FDA action on SPN-804 (ER oxcarbazepine), expected in October. We view the SPN-804 application, filed via the 505(b)(2) pathway, as a relatively low risk filing. With potentially two FDA-approved epilepsy products on the market in 2013 and upside from an advancing neuropsychiatric pipeline, we view SUPN shares as attractive in the context of a market cap under $400M. We reiterate our Overweight rating and are raising our PT to $15 from $12 (we are using a higher P/E (11x versus 9x) to better reflect the depth of SUPN's pipeline).”
Supernus Pharmaceuticals closed on Friday at $12.48.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
We simplify the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in